OpenEvidence is a medical AI platform that delivers answers grounded in peer-reviewed research to healthcare professionals, with a focus on U.S. clinicians who need reliable evidence at the point of care. It combines content from major medical publishers with an AI interface designed for clinical questions.
Content Agreements with Leading Publishers
OpenEvidence has signed content agreements with NEJM, JAMA, Nature, NCCN, Cochrane, and more. These agreements allow the platform to include full-text clinical findings, figures, tables, and multimedia from The New England Journal of Medicine, JAMA and the JAMA Network specialty journals, Nature and the Nature Portfolio, and Cochrane Systematic Reviews. For oncology, OpenEvidence includes NCCN Guidelines® Treatment Algorithms. This depth of source material distinguishes OpenEvidence from general-purpose AI tools that may not have licensed access to the same peer-reviewed literature.
The platform supports tasks such as writing prior authorization letters, asking about treatment options, and asking about drug dosing. These capabilities are presented as starting points for clinical workflows, and the answers are grounded in the licensed content. OpenEvidence is HIPAA compliant, which matters for clinicians who handle protected health information. The interface includes a "New Visit" feature, suggesting a session-based approach to organizing queries.
OpenEvidence collaborates with leading medical societies, including NCCN, AAP, ACC, ADA, AAFP, NORD, ACOG, AUA, AAO, ACEP, and more. These partnerships help align the platform with specialty guidelines and clinical priorities. For clinicians in fields such as oncology, cardiology, obstetrics, and urology, the involvement of relevant societies may add confidence that the content reflects current specialty thinking.
OpenEvidence states that it does not sell or share user searches or other content submitted to the platform. It does share limited information with third parties to measure the effectiveness of advertising that promotes OpenEvidence. Users can opt out of data sharing by clicking "Opt-out of data sharing" and saving their preferences. This opt-out is available directly in the privacy banner, and the platform confirms when the preference has been honored.
OpenEvidence is free and unlimited for healthcare professionals. The pricing and plans pages on the official website return 404 errors, so no additional pricing tiers or details are available. The free access appears to be limited to verified U.S. healthcare professionals, based on the information provided. Clinicians outside the United States may not have the same access, and no international pricing or availability details are provided.
OpenEvidence is not a general-purpose AI research assistant; it is a specialized medical knowledge platform. Its value depends on the breadth and currency of its licensed content, which includes major journals and society guidelines. The platform's privacy controls give users some choice over data sharing for advertising measurement. However, the lack of a public pricing page and the U.S.-only verification requirement may limit transparency for some users. For U.S. clinicians seeking evidence-based answers without leaving their workflow, OpenEvidence offers a focused alternative to broader AI search engines.